Results 51 to 60 of about 50,426 (246)
Alopecia areata – Current understanding and management [PDF]
, 2022 Alopecia areata (AA) is a chronic, immune-mediated disease characterized by acute or chronic non-scarring hair loss, with a heterogeneity in clinical manifestations ranging from patchy hair loss to complete scalp and body hair loss. An overview of the up-
Blume‐Peytavi, Ulrike +5 more
core +1 more source
Dermatology and Therapy, 2020 Introduction Cyclosporine is commonly used in treatment for alopecia areata. It can be administered as a monotherapy or in combination with systemic corticosteroids, with various outcomes.
Joanna Nowaczyk +4 more
doaj +1 more source
Autoantibodies to IL-17A may be correlated with the severity of mucocutaneous candidiasis in APECED patients. [PDF]
, 2014 The relative roles of various autoantibodies against IL-17-type cytokines in susceptibility to chronic mucocutaneous candidiasis (CMC) in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) remain poorly defined.
Csorba, Gabriella +5 more
core +1 more source
Is Alopecia a Clinical Symptom in Kawasaki Disease? [PDF]
Journal of Kerman University of Medical Sciences, 2014 A 20-months-old infant was admitted with prolonged fever, bilateral non-purulent conjunctivitis, strawberry tongue, lip cracking and maculopapular rash. Left branch coronary aneurysm formation was detected in Color-Doppler echocardiography. The diagnosis
Mohammad Mehdi Bagheri +3 more
doaj
Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
Dermatology Research and Practice, 2023 Background. Alopecia areata (AA) is a common form of noncicatricial hair loss of unknown cause, affecting 0.1-0.2% of the general population. Most evidence supports the hypothesis that it is disease of the hair follicle of autoimmune nature mediated by T-
Zainab A. Kamil +2 more
doaj +1 more source
Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
Frontiers in Medicine, 2023 Alopecia areata (AA) is a non-scarring hair loss disorder. Alopecia totalis (AT) and alopecia universalis (AU) are the severe subtypes of AA. Age of onset before 6 years of age, disease duration of more than 1 year, and extensive alopecia involving more ...
Lu Cai +7 more
doaj +1 more source
Computer-guided concentration-controlled trials in autoimmune disorders [PDF]
, 1993 A randomized concentration-controlled clinical trial (RCCCT) is an alternate experimental design to the standard dose-controlled study. In a RCCCT, patients are randomly assigned to predefined plasma or blood drug concentration ranges (low, medium, and ...
Doyle, H +7 more
core +1 more source
Acta Dermato-Venereologica, 2018 Treatment of alopecia totalis and alopecia universalis is often challenging and unsatisfactory. Recently, Janus kinase inhibitor has shown promising results.
Jung-Won Shin +6 more
doaj +1 more source
Journal of Dermatology and Dermatologic Surgery, 2021 Janus kinase (JAK) inhibitors have been identified as an effective treatment option for severe alopecia areata (AA), but response is variable among patients.
Erinolaoluwa F Araoye, Crystal Aguh
doaj +1 more source
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study
Vaccines, 2022 Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 ...
Francesco Tassone +5 more
doaj +1 more source